v3.26.1
Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Bayer (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Disaggregation of Revenue [Line Items]    
Revenues $ 3,605.4 $ 3,028.7
Bayer | Rest Of World | Regeneron's share of profits | Collaboration revenue    
Disaggregation of Revenue [Line Items]    
Revenues 240.0 317.3
Bayer | Rest Of World | Reimbursement for manufacturing of commercial supplies | Collaboration revenue    
Disaggregation of Revenue [Line Items]    
Revenues 47.3 26.6
Bayer | Rest Of World | Reimbursement of R&D expenses, net of Regeneron's obligation for its share of Bayer R&D expenses | Reduction of R&D expense/(R&D expense)    
Disaggregation of Revenue [Line Items]    
Revenues $ 1.0 $ (9.4)